Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection

George V Papatheodoridis; Spilios Manolakopoulos

Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection

Curr Opin Mol Ther. 2006 Aug;8(4):352-7.

Authors

George V Papatheodoridis¹, Spilios Manolakopoulos

Affiliation

¹ 2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, 114 Vas Sofias Avenue, Athens 11527, Greece. [email protected]

PMID: 16955699

Abstract

LG Life Sciences Ltd (formerly LG Chem Ltd), in collaboration with Anadys Pharmaceuticals Inc, is developing LB-80380 (PMCDG dipivoxil), an orally available lead compound in a series of phosphonate nucleotides, for the potential treatment of hepatitis B virus infection. In April 2003, phase II trials were initiated, the results of which were reported in February 2006. LB-80380 is the prodrug of LB-80317 (PMCDG), another compound from this series.

Publication types

Review

MeSH terms

Animals
Antiviral Agents / chemistry
Antiviral Agents / pharmacokinetics
Antiviral Agents / therapeutic use*
Clinical Trials as Topic
Guanine / analogs & derivatives*
Guanine / chemistry
Guanine / pharmacokinetics
Guanine / therapeutic use
Hepatitis B / drug therapy*
Humans
Organophosphonates / chemistry
Organophosphonates / pharmacokinetics
Organophosphonates / therapeutic use*

Substances

((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl
Antiviral Agents
Organophosphonates
Guanine